Dyslipidemia

Type: Keyphrase
Name: Dyslipidemia
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Dyslipidemia and Hypertension Control in HIV-Positive Patients

Among patients infected with HIV, whose lifespan as a group has been considerably extended by antiretroviral therapy, cardiovascular disease is now a major cause of morbidity and mortality. HIV-infected patients have a twofold increased risk for myocardial ... [Published Consultant Live - 8 hours ago]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Report Published: "Dyslipidemia - Pipeline Review, H2 2014"

Boston, MA -- ( ReleaseWire ) -- 09/11/2014 -- Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H2 2014', provides an overview of the Dyslipidemia's therapeutic pipeline.This report provides comprehensive information on the therapeutic development ... [Published SBWire - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Orexigen's Obesity Drug Gets FDA Approval

The US Food and Drug Administration (FDA) has approved the New Drug Application for Orexigen's anti-obesity drug, Contrave. This will be the third anti-obesity drug to hit the market after the June 2012 approval of Arena's Belviq and Vivus' QsymiaPage ... [Published Bidness Etc - Sep 11 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

By a News Reporter-Staff News Editor at Cardiovascular Week Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced that it has received very positive results in its Phase 2b TULIP clinical ... [Published Pharmacy Choice - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Control of Dyslipidemia and Hypertension in HIV Outpatients

Merle Myerson, MD, EdD, Eduard Poltavskiy, BS, Ehrin J. Armstrong, MD, MSc, Shari Kim, MS, Victoria Sharp, MD, Heejung Bang, PhDDisclosuresJ Acquir Immune Defic Syndr. 2014;66(4):370-377.Abstract and Introduction AbstractObjective: Patients with ... [Published General Medicine eJournal - Sep 08 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Dumaguing: Angina, Infarction and Ischemia

PATIENTS diagnosed to have heart disease or the more inclusive term, "cardovascular diseases" have heard these three words one way or another. Probably, this is the reason why, in our outreach sorties to different sectors of the community in Baguio and ... [Published Sun Star Network - Sep 05 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 4 reports

Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has received very positive results in its Phase 2b TULIP clinical trial,Click to Continue » ... [Published Fort Mills Times - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 1 reports

Social phenomena,air jordan 11 uk

Social phenomena and non-evaluation, ethical standards andprinciples in the social value orientation in cognition, can be put tothe test during exercise, air jordan 11 uk so people think that competitive sport can test the personal ability toadapt to ... [Published Student Village - Aug 28 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Decision Resources Group Triples Coverage On U.S. Longitudinal Patient Claims Data Analytics

BURLINGTON, Mass. , Aug. 18, 2014 /PRNewswire/ -- Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series , which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's ... [Published CEOWorld Magazine - Aug 18 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Combination of Alcohol and Fructose Exacerbates Metabolic Imbalance in Terms of Hepatic Damage, Dyslipidemia, and Insulin Resistance in Rats

by Salamah Mohammad Alwahsh, Min Xu, Frank Christian Schultze, Jörg Wilting, Sabine Mihm, Dirk Raddatz, Giuliano RamadoriAlthough both alcohol and fructose are particularly steatogenic, their long-term effect in the development of a metabolic syndrome ... [Published Plosone.org - Aug 07 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia

BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages ... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
First reported May 01 2014 - Updated May 01 2014 - 3 reports

The National Lipid Association Releases Draft Recommendations for Patient-Centered Treatment of Dyslipidemia

ORLANDO, Fla.--(EON: Enhanced Online News)--The National Lipid Association recently convened an Expert Panel to draft a document that would serve as guidance to clinicians for treating patients with dyslipidemia. ... [Published EON Science - May 01 2014]
Entities: Lipid, Dyslipidemia

Quotes

John Kastelein, CSO and co-founder of Dezima said: "The results emphasize that TA-8995 robustly lowers all atherogenic lipoproteins, LDL-C, the entity of non HDL-C, apoB as well as Lp(a), compatible with very significant reductions of cardiovascular risk."
"The Arrigo Recordati International Prize for Scientific Research was established to carry on my father's legacy and to inspire scientists and researchers to make important discoveries benefiting people worldwide" stated Giovanni Recordati, his eldest son and current Chairman and CEO of Recordati
which is the truth. "Except Brazil, European powerhouse Slovenia also"
Dr. Kwiterovich was the author of more than 200 peer-reviewed publications and 75 academic reviews and book chapters. His "The Johns Hopkins Complete Guide to Preventing and Reversing Heart Disease" and "Beyond Cholesterol" remain two popular clinical texts

More Content

All (37) | News (21) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (4) | Press Releases (0)
sort by: Date | Relevance
Dyslipidemia and Hypertension Control in HIV-Po... [Published Consultant Live - 8 hours ago]
Orexigen's Obesity Drug Gets FDA Approval [Published Bidness Etc - Sep 11 2014]
Report Published: "Dyslipidemia - Pipeline Revi... [Published SBWire - Sep 11 2014]
Role of Nutrition and Nutritional Supplements i... [Published Theheart.org - Sep 10 2014]
Dezima Reports Positive Results in its Phase 2b... [Published Pharmacy Choice - Sep 08 2014]
Control of Dyslipidemia and Hypertension in HIV... [Published General Medicine eJournal - Sep 08 2014]
Dumaguing: Angina, Infarction and Ischemia [Published Sun Star Network - Sep 05 2014]
RECORDATI : The eight edition of the Arrigo Rec... [Published 4 Traders - Aug 30 2014]
Dezima Reports Positive Results in its Phase 2b... [Published Fort Mills Times - Aug 29 2014]
Dezima Reports Positive Results in its Phase 2b... [Published Digital Journal - Aug 29 2014]
Dezima Reports Positive Results in its Phase 2b... [Published CEOWorld Magazine - Aug 29 2014]
Dezima Reports Positive Results in its Phase 2b... [Published Business Wire Health News - Aug 29 2014]
Social phenomena,air jordan 11 uk [Published Student Village - Aug 28 2014]
Pleiotropic Effects of Lipid Genes on Plasma Gl... [Published Diabetes - Aug 24 2014]
Dr. Peter O. Kwiterovich Jr., expert on lipid d... [Published Baltimore Sun - Aug 20 2014]
Jazz Pharmaceuticals Announces U.S. Commercial ... [Published Longitude Capital - Aug 19 2014]
Decision Resources Group Triples Coverage On U.... [Published CEOWorld Magazine - Aug 18 2014]
News from the European Atherosclerosis Society ... [Published British Journal of Cardiology - Aug 13 2014]
Practice Guidelines for the Management of LDL-R... [Published Theheart.org - Aug 11 2014]
Combination of Alcohol and Fructose Exacerbates... [Published Plosone.org - Aug 07 2014]
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
Viking Signs Broad Licensing Deal With Ligand P... [Published Marketwire - Breaking News Releases - May 22 2014]
Research and Markets: Dyslipidemia - Pipeline R... [Published Business Wire Health News - May 07 2014]
The National Lipid Association Releases Draft R... [Published EON Science - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Science: Science News - May 01 2014]
The National Lipid Association Releases Draft R... [Published Business Wire Health News - May 01 2014]
Data Showed After 52 Weeks, LIVALO® (pitavastat... [Published PR Newswire: General Business - May 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Dezima Reports Positive Results in its Phase 2b... [Published Business Wire Health News - Aug 29 2014]
NAARDEN, Netherlands--(BUSINESS WIRE)--Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has received very positive results in its Phase 2b TULIP clinical trial, a double ...
Amgen's Evolocumab is Set to Become the Clinica... [Published PR Newswire: Entertainment & Media - Jul 21 2014]
BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that Amgen's evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia. The competitive advantages ...
Research and Markets: Product and Pipeline Anal... [Published Business Wire Health News - Jun 27 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dk238k/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market" report to their offering. ...
Mixed Dyslipidemia Global Clinical Trials Revie... [Published PR Newswire: Health - Jun 03 2014]
NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014... ...
Research and Markets: Mixed Dyslipidemia Global... [Published Business Wire Professional Services News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s8k8lc/mixed) has announced the addition of the "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" report to their offering. Our clinical trial report, ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.